LKLeo A. Kim

Leo A. Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leo A. Kim has a total of 541 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ROCK signaling at the interface of fibrosis and neurodegeneration: mechanisms and therapeutic potential

    by Jeysson Sanchez-Suarez, Yvonne Adu-Rutledge, Kunho Bae, Hyungwoo Lee, Anton Lennikov, Nakyung Ryoo, Anil Upreti, Aruvi Vijikumar, William P. Miller, Leo A. Kim

    Rho-associated coiled-coil containing protein kinases 1 and 2 (ROCK1 and ROCK2) regulate cytoskeletal dynamics, actomyosin contractility, extracellular matrix remodeling, and responses to mechanical stress. In the eye and central nervous system (CNS), these functions intersect with fibrocontractile scarring, neuronal dysfunction, impaired regeneration, and neuroinflammation. This review examines ROCK signaling at the interface of ocular fibrosis and neurodegeneration, emphasizing the retina as a setting in which neural injury and pathological remodeling can coexist. We outline the physiological and pathological consequences of ROCK-mediated mechanotransduction, using peripheral fibrosis only as brief comparative context, and examine its relationship with MRTF/SRF and YAP/TAZ transcriptional modules. We then assess evidence from ocular fibrotic disease, axonal regeneration, synaptic plasticity, microglial activation, and CNS injury-associated scarring, distinguishing direct ROCK-dependent mechanisms from extrapolation across tissues. ROCK1 and ROCK2 display overlapping functions with context-dependent specialization, but current evidence does not support a universal division of labor between the isoforms. Single-cell, spatial, and multi-omics approaches offer opportunities to identify disease-relevant cell populations, although transcript abundance alone cannot establish kinase activity or therapeutic dependence. Finally, we consider ocular and neural therapeutic development, including isoform-informed targeting, local delivery, and mechanism-aligned combinations. The central challenge is to suppress persistent pathological remodeling while preserving physiological repair and beneficial neural or glial responses. Resolving the cellular, spatial, and temporal requirements for ROCK signaling will be essential for testing whether antifibrotic and neuroprotective effects can be achieved together.

  • Open Access

    Contemporary patterns and factors associated with registry-coded proliferative vitreoretinopathy after retinal detachment repair in the IRIS® Registry

    by Kunho Bae, Eric A. Goldberg, Connor J. Ross, Hyungwoo Lee, Jeysson Sanchez-Suarez, Na-Kyung Ryoo, William P. Miller, Tobias Elze, Rishi P. Singh, Leo A. Kim

    Background: Proliferative vitreoretinopathy (PVR) remains a major cause of failure after retinal detachment (RD) repair. We evaluated the incidence, timing, and factors associated with registry-coded PVR after primary RD repair. Methods: This retrospective cohort study included eyes undergoing incident primary RD repair from January 2017 through December 2024 in the American Academy of Ophthalmology IRIS ® Registry, with more than 6 months of follow-up and postoperative data available through July 31, 2025. Registry-coded PVR was identified using H35.2x diagnoses recorded in the operated eye. Diagnoses recorded within ± 14 days of RD repair were classified as concurrent registry-coded PVR, whereas those recorded more than 14 days after repair were classified as delayed registry-coded PVR. We described the proportion of eyes with concurrent registry-coded PVR and the cumulative incidence and timing of delayed registry-coded PVR. Multivariable Cox proportional hazards models incorporating time-varying ocular covariates evaluated factors associated with delayed registry-coded PVR. Results: Among 202,975 eyes, 1.37% had concurrent registry-coded PVR. The 1-year cumulative incidence of delayed registry-coded PVR was 2.20% (95% confidence interval [CI], 2.14–2.27). Younger (< 40 years) and older (≥ 70 years) age groups had higher hazards than those aged 60–69 years, with age-related associations varying over follow-up. Low ZIP code–level household income (<$35,000 vs. $35,000–$74,999; hazard ratio [HR], 1.48; 95% CI, 1.23–1.77) and rural residence (HR, 1.22; 95% CI, 1.13–1.33) were independently associated with increased hazard. Compared with pars plana vitrectomy, complex RD repair (HR, 1.65; 95% CI, 1.52–1.79) and pneumatic retinopexy (HR, 1.20; 95% CI, 1.09–1.32) were associated with higher hazard, whereas scleral buckling was associated with lower hazard (HR, 0.66; 95% CI, 0.55–0.78). Vitreous hemorrhage, macular puckering, and glaucoma first recorded after the landmark were associated with higher hazard. Preexisting pseudophakia or concurrent cataract extraction was associated with lower hazard (HR, 0.90; 95% CI, 0.84–0.96). Conclusions: Delayed registry-coded PVR was recorded in approximately 1 in 45 eyes within 1 year after primary RD repair. Its occurrence was associated with age, socioeconomic characteristics, surgical approach, postoperative ocular conditions, and cataract surgery timing, with age-related associations varying over follow-up. Clinical trial number: Not applicable.

  • Open Access

    An intraocular oxygenated emulsion suppresses retinal fibrosis by inhibiting hypoxia-driven bioenergetic shifts and mesenchymal transformation

    by Yihe Chen, Binapani Mahaling, Lei Xi, Qiaoran Qi, Maryam Shayan, Anil Upreti, Zhirong Lin, Asmaa Zidan, Qiurong Zhu, Olivia Qin, et al.

    Fibrosis drives progressive organ dysfunction, yet targeted therapies remain limited. In the eye, proliferative vitreoretinopathy (PVR) is a blinding fibrotic disease without approved medical treatment. Here, single-cell RNA sequencing of human PVR membranes revealed convergent activation of hypoxia-responsive programs across major cell populations. Using a molecular probe, we directly validated spatial and temporal hypoxia in an open-globe injury model that recapitulates traumatic PVR. Intravitreal delivery of a supersaturated oxygen emulsion (SSOE) preserved retinal function while reducing fibrocellular membrane formation and inflammation. Mechanistically, human PVR cells exhibited metabolic shifts toward glycolysis alongside epithelial-mesenchymal transition (EMT). SSOE corrected cellular hypoxia, preserved mitochondrial integrity, suppressed glycolytic shift, and inhibited EMT in human retinal pigment epithelial cells, while reducing spontaneous contractility in primary human PVR cell cultures. Together, these findings identify hypoxia as a critical driver of retinal fibrosis and support localized intraocular oxygenation as a viable therapeutic strategy for preventing fibrotic vision loss.

  • Open Access

    Deep Learning–Guided Retinal Vascular Morphometric Quantification in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Mouse Models

    by Hyungwoo Lee, Na-Kyung Ryoo, Said Arevalo-Alquichire, Kunho Bae, William P. Miller, Joseph F. Arboleda-Velasquez, Leo A. Kim

  • Open Access

    Inhibition of runt related transcription factor 1 with Ro24-7429 improves lung function in experimental models of idiopathic pulmonary fibrosis

    by Thomas I. Hirsch, William P. Miller, Savas T. Tsikis, Said Jose Arevalo-Alquichire, Bryan A. Kaplan, Karim W. Barake, Audrey L. Gunawan, Timothy E. Vanderleest, Aruvi Vijikumar, Jeysson Sanchez-Suarez, et al.

    Idiopathic Pulmonary Fibrosis (IPF) is a life limiting disease with debilitating symptoms and limited therapeutic options. The development of IPF is a chronic process involving epithelial-to-mesenchymal transition (EMT), perpetuated by fibroblast proliferation and abnormal wound healing during which normal lung tissue is replaced with collagen impairing lung expansion and aeration. We targeted Runt-related transcription factor 1 (RUNX1), a transcription factor that coordinates EMT upon stimulation by key inflammatory mediators, such as TGF-β and TNF-α. In a previous investigation performed during the COVID19 pandemic, inhibiting RUNX1 with the small molecule inhibitor Ro24-7429 (Ro24), which has undergone testing in humans with a favorable side effect profile, was linked to a robust amelioration of lung fibrosis and decreased markers of fibrosis. In prior work utilizing Ro24, no studies of pulmonary function were performed and investigation of RUNX1 in human lung tissue was limited. Herein, we identified abnormally elevated RUNX1 in diseased human lung tissue of seven patients with IPF, implicating the transcription factor in the progression of the disease. Targeting RUNX1 with the small molecule inhibitor, Ro24 improved lung function and exercise tolerance in a murine model of bleomycin-induced pulmonary fibrosis. In comparison to the currently used clinical standards nintedanib and pirfenidone, Ro24 improved exercise tolerance in bleomycin-challenged mice. Thus, Ro24 has strong translational potential as a preventative therapy for patients with IPF.

  • Open Access

    Influence of Anti-VEGF Injections on Longitudinal Changes in Vascular Metrics Measured by OCTA in Age Related Macular Degeneration: A Retrospective Real-World Study

    by Ying Zhu, Selin Gumustop, Leiyu Wang, Aurora Tong, Xinyi Ding, Ioanna Ploumi, Francesco Romano, Chong Chen, Kayla Nodecker, Shivesh Shah, et al.

    To investigate the possible influence of repeated anti-VEGF injections on vascular metrics measured by optical coherence tomography angiography (OCTA) in patients with age-related macular degeneration (AMD). This retrospective longitudinal study included AMD patients with a follow-up time of at least 18 months from 2019 to 2024. Swept-source OCTA was performed on all eyes. Based on whether an eye received injections or not during follow-up, all eyes were divided into two groups (non-injection group only included non-exudative AMD). Vessel density, Vessel skeleton density in the superficial, deep, and retina slab, as well as foveal avascular zone (FAZ) size, circularity and perimetry of Angio 6mm×6mm were calculated. Change in vascular metrics between baseline and last follow-up were compared between the two groups using t-test or Mann–Whitney U-test. Correlation between change in vascular metrics and visual acuity was investigated by Spearman’s Rank Correlation test. A total of 164 eyes from 107 patients were included. The average follow-up time was 34 months. No statistically significant difference in baseline vascular metrics was detected between the injection group (57 eyes) and non-injection (107 eyes) group. The injection group received 12.56 injections during follow-up. Among all the parameters, only change in FAZ size during follow-up showed a statistically significant difference between the two groups (0.03 vs. 0.02 mm2, P=0.043). No correlation was found between change in vascular metrics and change in visual acuity (P>0.05). In this retrospective longitudinal study of 164 eyes, repeated intravitreal anti-VEGF injections were associated with no relevant significant changes in OCTA vascular metrics over time.

  • Assessing Retinal Non-Perfusion With Ultra-Widefield OCT-A: Correlations With Diabetic Retinopathy Severity and Peripheral Lesions

    by Selin S. Gumustop, Xinyi Ding, Yi Stephanie Zhang, Ioanna Ploumi, Ying Zhu, Leiyu Wang, Francesco Romano, Itika Garg, Chong Chen, Kayla N. Nodecker, et al.


  • Swept-Source Optical Coherence Tomography Angiography Vascular Metrics as Biomarkers for Renal Function in Patients with Diabetes Mellitus

    by Itika Garg, Margaret Duich, Chibuike Uwakwe, Karen M. Wai, Jocelyn M. Rodriguez, Edward S. Lu, Ying Cui, Rongrong Le, Raviv Katz, Ines Lains, et al.


  • Open Access

    Advancing perspectives on proliferative vitreoretinopathy: Updates in experimental research and emerging clinical treatments

    by Fang Zheng, Elie Motulsky, Luiz Roisman, Xiaoyun Fang, Kanae Fukutsu, Chee Wai Wong, Veluchamy Amutha Barathi, Edmund Wong, Andrew S.H. Tsai, Leo A. Kim, et al.